BioCryst Pharmaceuticals Inc
(STU:BO1)
€
7.362
-0.256 (-3.36%)
Market Cap: 1.52 Bil
Enterprise Value: 1.97 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 71/100 BioCryst Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023 / 10:00PM GMT
Release Date Price:
€7.88
(+1.00%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
Good afternoon. Thanks for joining us. Welcome back to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the Senior SMID biotech analyst here. It's my pleasure to have our next presenting company, BioCryst Pharmaceuticals, which, as a point of trivia, is one of my longest covered names, both as a lead and as an associate analyst. So I've known Jon now many years. Sitting next to me is, of course, CEO, Jon Stonehouse.
Welcome back to Vegas, Jon. Thanks for coming.
Jon P. Stonehouse
BioCryst Pharmaceuticals, Inc. - CEO, President & Executive Director
Yes. I -- we were talking about how many years. It's probably too long to admit, but it's great to be back here.
Tazeen Ahmad;Jon P. Stonehouse
BofA Securities, Research Division - MD in Equity Research & Research Analyst;BioCryst Pharmaceuticals, Inc. - CEO, President
Yes, we're always happy to have you.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot